Market Pulse

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

AirAsia  in India

AirAsia in India

AirAsia India launch seen in Q4; may order 50 more Airbus jets: CEO.  Full Article 

Jet, Spicejet Results

Jet, Spicejet Results

Jet Airways, SpiceJet report quarterly losses.  Full Article | Related Story 

Tata Steel Shines

Tata Steel Shines

Tata Steel surges; Q4 operating profit beats f'cast.  Full Article 

Gold Outlook

Gold Outlook

Gold faces more pressure as inflation stays tame.  Full Article 

RBI's May Review

RBI's May Review

Subbarao overrules panel view on rate action in May.  Full Article 

Steel Output

Steel Output

Jindal to expand steel output, buy mines in West Africa.  Full Article 

Abe's Agenda

Abe's Agenda

Special Report - The deeper agenda behind "Abenomics".  Full Article 

Revenge of Markets

Revenge of Markets

For months, markets have been dancing to central bankers' tune, but that may now be changing, writes James Saft.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Dishman close to deal with AstraZeneca, Merck-source

Related Topics

MUMBAI | Tue Aug 19, 2008 4:07pm IST

MUMBAI (Reuters) - Dishman Pharmaceuticals & Chemicals Ltd is close to signing contracts with U.S. Merck & Co Inc and AstraZeneca for supplying bulk drugs, a source close to the deal said on Tuesday.

"The contracts are expected to be signed in a month's time," the source, who declined to be named told Reuters.

Dishman already has a long-term contract manufacturing deal with Dutch Solvay for supplying bulk drugs and intermediates.

Global pharmaceutical giants are increasingly outsourcing drug manufacturing to companies in India as they seek to benefit from lower manufacturing costs here.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.